Zhi Tong Cai Jing·2025-09-03 06:53Core Viewpoint - Fuhong Hanlin's stock rose nearly 6% following the FDA approval of two biosimilar products, BILDYOS and BILPREVDA, in collaboration with Organon, enhancing its market position in the U.S. biosimilar sector [1] Group 1: Company Developments - Fuhong Hanlin's stock price increased by 5.78%, reaching 81.45 HKD, with a trading volume of 48.73 million HKD [1] - The FDA approved BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp), which are biosimilars to PROLIA and XGEVA, respectively [1] - The approval covers all indications for the original products in the U.S. market [1] Group 2: Partnership and Market Impact - In 2022, Fuhong Hanlin entered into a licensing and supply agreement with Organon, granting Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1] - The approval of these products strengthens Organon's biosimilar portfolio in the U.S., which has been developed over eight years and spans five major therapeutic areas [1]